News

Cetuximab Yields Benefits in Colorectal Cancer

Publish date: May 15, 2007
PDF Download

 

Overall survival increased from a median of 4.6 months to 6.1 months with cetuximab. DR. JONKER

Pages

Recommended Reading

Bevacizumab Disappoints in Pancreatic Cancer
MDedge Internal Medicine
Asymptomatic Celiac: Does Treatment Help or Hurt?
MDedge Internal Medicine
Aspirin, NSAIDs Risky for Colorectal Ca Prevention
MDedge Internal Medicine
Fatalism Tied to Lower Colorectal Screening Rates
MDedge Internal Medicine
Screen Sleep Disorder Patients for GI Reflux : Treating gastrointestinal reflux can improve sleep—and treating sleep disorders can improve reflux.
MDedge Internal Medicine
Screening for Apnea Cuts ICU Admissions After Gastric Bypass
MDedge Internal Medicine
Surgery Still an Option For Some GERD Patients
MDedge Internal Medicine
Injected Carbon Beads May Curb Fecal Incontinence
MDedge Internal Medicine
Push Diet, Exercise; Consider Glitazones for NASH : Patients who achieved greater than 9% weight loss had improvements in NASH activity scores.
MDedge Internal Medicine
More Techniques for Barrett's Ablation Are Now Available
MDedge Internal Medicine